I-Corps: Commercialization Investigation of the Navipoint Clinical Genomics Platform

I-Corps项目团队的技术是基因组分析平台Globus genomics，它可以：以电子方式移动大型基因组数据集，允许研究人员使用图形用户界面定义自定义分析工作流程，在基因组数据集上大规模执行他们的工作流程，并产生有价值的研究结果，帮助推进对复杂疾病遗传基础的理解。遗传和基因组分析是快速发展的精密医学前沿的一部分，呈指数级增长。研究人员和临床医生都在转向基因组学来帮助指导诊断、药物发现和治疗，以便以更有针对性和更有效的方式对抗各种疾病。从诊断到治疗的时间非常重视消除端到端瓶颈。鉴于分析的规模（和成本）不断增加，性能优化也必须与成本优化相结合。而且，随着算法、应用和技术的快速发展，必须汇集关键专业知识，以提供高度先进、集成良好且易于使用的解决方案。目前的方法已被证明过于僵化、缓慢、复杂和昂贵。它们需要大量的时间和金钱投入，而且很难找到专业知识，这远远超出了许多临床组织的能力。I-Corps团队旨在提供灵活、可扩展和优化的基因组学分析解决方案，以满足医院诊断实验室、基因检测服务提供商、转化医学研究所和制药研发团队的这些关键要求。有了这种类型的平台，卫生服务组织可以为患有各种遗传性疾病和失调的患者提供更有针对性、及时和有效的治疗。所提议的项目工作的目标包括更深入地了解需求的优先领域和详细的客户需求。这在很大程度上取决于客户访谈的广度和深度，以及团队商业模式和产品设计的不断发展。有了这种理解，团队将开始迭代开发工作，以获得快速的客户反馈，并朝着最小可行产品的定义工作。该团队计划在发现和初始部署阶段与医疗机构和基因检测公司密切合作。该平台的潜在贡献将包括：更快的基因组分析能力，改善临床环境中的诊断和治疗时间，以及直观的用户体验，使诊断医生和临床从业人员能够专注于患者护理，而不是软件复杂性和本地化的计算机硬件限制。

This I-Corps project team's technology is a genomics analysis platform, Globus Genomics, that can: electronically move large genomic data sets, allow researchers to define custom analytical workflows using a graphical user interface, execute their workflows on genomic data sets at scale, and generate valuable research results which help advance the understanding of the genetic basis of complex diseases. Genetic and genomic analysis is growing exponentially as part of the rapidly evolving frontier of precision medicine. Researchers and clinicians alike are turning to genomics to help guide diagnosis, drug discovery, and treatment in order to combat a variety of diseases in a much more targeted and effective manner. Time-to-diagnosis and time-to-treatment place a premium on removing end-to-end bottlenecks. Given the increasing scale (and costs) of analysis - performance optimization must also be combined with cost optimization. And, with a rapidly evolving state-of-the-art in terms of algorithms, applications and technologies, critical expertise must be assembled to deliver highly advanced, well integrated, and easy-to-use solutions. Current approaches have proven to be too rigid, slow, complex and costly. They require substantial investments of time, money and hard to find expertise, that goes well beyond the capabilities of many clinical organizations. This I-Corps team seeks to provide a flexible, scalable and optimized genomics analysis solution in order to meet these critical requirements for diagnostic labs in hospital settings, genetic testing service providers, translational medicine institutes and pharmaceutical R&D groups. With this type of platform in place, health delivery organizations can provide more targeted, timely and effective treatment to their patients suffering from a broad range of heritable diseases and disorders. The goal of the proposed project efforts include getting a much more in-depth understanding of the prioritized areas of needs and detailed customer requirements. This will be largely driven by breadth and depth of customer interviews along with an evolving formulation of the team's business model and product design. With this understanding, the team will embark on an iterative development effort to gain rapid customer feedback and work towards the definition of a minimum viable product. The team plans to work closely with both health care organizations and genetic testing companies in the discovery and initial deployment stages. The potential contribution of the proposed platform will include: much more rapid genomic analysis capabilities, improved time-to-diagnosis and time-to-treatment in a clinical setting, and an intuitive user experience to allow diagnosticians and clinical practitioners to focus on patient care instead of software complexities and localized computer hardware limitations.